Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sosei Group ( (JP:4565) ) has provided an announcement.
Nxera Pharma said its partner Centessa Pharmaceuticals has agreed to be acquired by Eli Lilly, handing the US drugmaker ownership of a jointly discovered orexin receptor 2 agonist pipeline for sleep-wake disorders. The deal leaves Nxera’s contractual rights intact, including milestone payments, royalties on OX2R agonists such as cleminorexton, and its equity stake in Centessa.
Management framed the transaction as further validation of Nxera’s Cambridge-based CNS drug discovery heritage and its proprietary NxStaR and NxWave platforms, which have generated candidates now progressing toward late-stage development with leading pharma companies. Nxera plans to harness this momentum for its wholly owned metabolic and rare endocrine disease pipeline, alongside a separate multi-target collaboration with Lilly that could yield up to $694 million in milestones plus tiered royalties.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen976.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines for patients with unmet medical needs in Japan and globally. It combines an agile commercial business in Japan and the broader APAC region with an extensive pipeline powered by its NxWave GPCR structure-based drug discovery platform, operating from hubs in Japan, the UK, Switzerland and South Korea.
Average Trading Volume: 741,222
Technical Sentiment Signal: Sell
Current Market Cap: Yen78.46B
For detailed information about 4565 stock, go to TipRanks’ Stock Analysis page.